Efficacy News and Research

RSS

Broad application of bipolar diagnosis in children may do more harm than good

Troubled children diagnosed with bipolar disorder may fare better with a different diagnosis, according to researchers at The Hastings Center.

18 Mar 2010

StemCells granted UK patent covering true rat stem cells and genetically engineered rats

StemCells, Inc. announced today that the United Kingdom (UK) Intellectual Property Office has granted patent number GB2451523 with broad claims covering true (germline competent) rat stem cells and genetically engineered rats derived from these cells. The patented technology is expected to have significant utility to academic and pharmaceutical industry researchers by enabling them to create novel rat models for the study of human diseases. Both mice and rats are used by scientists to model various human diseases.

18 Mar 2010

Novelos Therapeutics Phase 3 trial of NOV-002 in advanced NSCLC fails to meet primary and secondary endpoints

Novelos Therapeutics, Inc., a biopharmaceutical company focused on the development of therapeutics to treat cancer and hepatitis, today announced that primary and secondary endpoints were not met in Novelos’ pivotal Phase 3 trial in advanced non-small cell lung cancer (NSCLC) with its lead product, NOV-002, in combination with first-line chemotherapy.

18 Mar 2010

Bailout stenting successful treatment for infants with constricted aortas

Cardiac interventionalists and surgeons at University Clinic in Leuven, Belgium have achieved successful stent implantation and follow-up coarctectomy in premature infants suffering from aortic coarctation. Full findings are published in the March issue of Catheterization and Cardiovascular Interventions, the official journal of The Society for Cardiovascular Angiography and Interventions.

18 Mar 2010

MR-guided ablation therapy may hold promise for treatment of prostate cancer recurrences

The first known patient cases using magnetic resonance-guided heat (laser interstitial thermal therapy) or cold (cryoablation) to treat prostate cancer recurrence after surgical removal of the prostate gland were presented by physicians at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa. Many of these patients have also failed salvage radiation treatment and are often presented with limited therapeutic options. MR-guided focal therapy offers a new treatment choice for patients because of the improved detection of early prostate cancer recurrences best seen with MR imaging.

18 Mar 2010

CYPHER Sirolimus-eluting Coronary Stent demonstrates efficacy advantages over Medtronic's Endeavor

Investigators reported the long-term follow-up of the largest randomized comparison between the CYPHER(R) Sirolimus-eluting Coronary Stent and Medtronic's Endeavor(R) Stent highlighting significant and sustained clinical differences. These important findings were presented at the American College of Cardiology annual meeting, (ACC 2010) in Atlanta and published on-line in the prestigious journal The Lancet.

18 Mar 2010

Bleach-based disinfectants more effective against noroviruses

Some 40% of commercial disinfectants used to clean surfaces are believed to be ineffective in eliminating noroviruses, a group of viruses responsible for more than half of all foodborne gastroenteritis outbreaks. According to a recent study published by Universit- Laval researchers in the Journal of Food Protection, only bleach-based disinfectants drastically reduce the concentration of these viruses.

18 Mar 2010

ETP releases presentation highlights of 2010 Epilepsy Pipeline Update Conference

The Epilepsy Therapy Project, a non-profit organization dedicated to accelerating new therapies for people living with epilepsy, today released presentation highlights following its successful 2010 Epilepsy Pipeline Update Conference held in San Francisco. Sponsored by ETP, this conference brings together leading clinical investigators, emerging CNS companies and academic innovators with investors and business development partners to facilitate professional collaboration, funding and partnerships that will accelerate patient access to new treatments.

18 Mar 2010

Prometheus Laboratories, Bayer Schering Pharma form research collaboration and license agreement

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a research collaboration and license agreement with Bayer Schering Pharma AG, Germany, a worldwide leading specialty pharmaceutical company. The collaboration partners Prometheus' proprietary oncology diagnostic platform with Bayer's broad oncology pipeline in an effort to stratify patients to appropriate drug candidates and potentially accelerate the development of novel oncology therapeutic products.

18 Mar 2010

Positive preliminary results from MediciNova's Phase Ib clinical trial of MN-221 for COPD

MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today reported positive preliminary results from a Phase Ib clinical trial to evaluate the safety and efficacy of MN-221 in patients with stable, moderate to severe chronic obstructive pulmonary disease (COPD). There were no clinically significant safety concerns noted. Preliminary results demonstrated clinically significant improvements in percent change in forced expiratory volume in one second (FEV(1)).

18 Mar 2010

OrbusNeich's Genous Bio-engineered R stent demonstrates long term clinical efficacy

OrbusNeich today announced that 12 month follow up data from real world patients demonstrated long term clinical efficacy of the company's Genous Bio-engineered R stent.

18 Mar 2010

Agendia to participate in groundbreaking clinical trial for breast cancer

Agendia, a world leader in molecular cancer diagnostics, announced today it will participate in the highly anticipated I-SPY 2 TRIAL for breast cancer, set to launch at the first of nearly twenty research sites.

18 Mar 2010

Phase 2a clinical trial results of CPEX Pharmaceuticals' Nasulin insulin

CPEX Pharmaceuticals Inc. today reported preliminary results related to its Phase 2a proof-of-concept clinical trial of the Company’s nasal insulin product, Nasulin™. The study was designed to evaluate the efficacy and safety of Nasulin versus placebo over a 6-week treatment period in subjects with Type 2 diabetes who were being treated with basal insulin and oral anti-diabetes agents.

18 Mar 2010

Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC

Alkermes, Inc. today announced the initiation of a multidose phase 1 clinical study of ALKS 37, an orally active, peripherally-restricted opioid antagonist with potential to block the effects of opioid agonists on gastrointestinal motility, commonly referred to as opioid-induced constipation (OIC). The randomized, double-blind, placebo-controlled, repeat-dose study will assess the safety, tolerability and pharmacokinetics of daily oral administration of two dose levels of ALKS 37 for a seven day period in approximately 24 healthy volunteers.

17 Mar 2010

Protalix BioTherapeutics commences clinical trial of human acetylcholinesterase for biodefense indications

Protalix BioTherapeutics, Inc. announced today that it has initiated a phase I clinical trial of PRX-105, the Company's plant cell expressed pegylated recombinant human acetylcholinesterase product candidate in development for biodefense indications. The trial is designed to study the safety of PRX-105 by administering a bolus intravenous injection of PRX-105 in healthy volunteers.

17 Mar 2010

TSO3 reports net loss of $9.2M for fiscal 2009

TSO3 Inc. an innovator in sterilization technology for medical devices in healthcare settings using ozone, posted sales totalling $1.3 million for the fiscal year ended December 31, 2009, compared to $2.2 million one year earlier. During the year, the Company sold five of its first generation STERIZONE(R) sterilizers and accessories, whereas it sold 13 in the preceding fiscal year.

17 Mar 2010

TRITON-TIMI 38 study evaluates response rates in patients with common genetic variant in ABCB1 gene

A new analysis of the TRITON-TIMI 38 study evaluated response rates in patients with a common genetic variant in the ABCB1 gene. Patients enrolled in the TRITON-TIMI 38 study were treated with dual antiplatelet therapy with either Plavix® (clopidogrel) plus aspirin or Effient® (prasugrel) plus aspirin and managed with percutaneous coronary intervention (PCI) following an acute coronary syndrome (ACS) event.

17 Mar 2010

Agilent Technologies introduces new ion exchange and size exclusion columns for analysis of bio-molecules

Agilent Technologies Inc. today announced the availability of new ion exchange and size exclusion columns specifically designed for the analysis of bio-molecules including monoclonal antibodies, recombinant proteins, peptides, vaccine products and DNA/RNA. The columns provide robust, reproducible and high-resolution solutions for biopharmaceutical manufacturers to effectively monitor the safety, efficacy and stability of their products.

17 Mar 2010

Avedro to acquire Corneal Collagen Crosslinking Phase III study rights from Peschke Meditrade

Avedro, Inc. today announced it has signed a definitive agreement with Swiss-based Peschke Meditrade GmbH to acquire the rights to its Phase III studies of Corneal Collagen Crosslinking for the treatment of progressive keratoconus and post LASIK ectasia. The two randomized, controlled, multi-site clinical trials are designed to assess the safety and efficacy of riboflavin/ultraviolet-A light for halting the progression of these degenerative disorders and the accompanying decline in patient’s visual acuity.

17 Mar 2010

Boston University's Technology Development Office completes exclusive license of Project RED to Engineered Care

Boston University's Technology Development Office, on behalf of Boston Medical Center, Northeastern University, and Massachusetts Institute of Technology (MIT), has completed the exclusive license of Project RED (Re-Engineered Discharge) to Engineered Care, Inc.

17 Mar 2010

Efficacy News and Research

Broad application of bipolar diagnosis in children may do more harm than good

StemCells granted UK patent covering true rat stem cells and genetically engineered rats

Novelos Therapeutics Phase 3 trial of NOV-002 in advanced NSCLC fails to meet primary and secondary endpoints

Bailout stenting successful treatment for infants with constricted aortas

MR-guided ablation therapy may hold promise for treatment of prostate cancer recurrences

CYPHER Sirolimus-eluting Coronary Stent demonstrates efficacy advantages over Medtronic's Endeavor

Bleach-based disinfectants more effective against noroviruses

ETP releases presentation highlights of 2010 Epilepsy Pipeline Update Conference

Prometheus Laboratories, Bayer Schering Pharma form research collaboration and license agreement

Positive preliminary results from MediciNova's Phase Ib clinical trial of MN-221 for COPD

OrbusNeich's Genous Bio-engineered R stent demonstrates long term clinical efficacy

Agendia to participate in groundbreaking clinical trial for breast cancer

Phase 2a clinical trial results of CPEX Pharmaceuticals' Nasulin insulin

Alkermes initiates multidose Phase 1 clinical study of ALKS 37 for OIC

Protalix BioTherapeutics commences clinical trial of human acetylcholinesterase for biodefense indications

TSO3 reports net loss of $9.2M for fiscal 2009

TRITON-TIMI 38 study evaluates response rates in patients with common genetic variant in ABCB1 gene

Agilent Technologies introduces new ion exchange and size exclusion columns for analysis of bio-molecules

Avedro to acquire Corneal Collagen Crosslinking Phase III study rights from Peschke Meditrade

Boston University's Technology Development Office completes exclusive license of Project RED to Engineered Care

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News